Verona Pharma
HOLDVerona Pharma can take its asthma and fever treatment to its next trial phase after approval by the Netherlands Ethics Committee.
A clinical update from the AIM-quoted company says its RPL554 treatment can now go to the final stage of its Phase I/IIa clinical trial. Analysts suggest London-based Verona should be well placed to have RPL554 licensed if it successfully completes this trial.
Verona, which seeks to research, discover and develop new therapeutic drugs for hay fever, asthma and and other chronic respiratory diseases, has been conducting the RPL554 trials at the Centre for Human Drug Research at Leiden in Holland. Not wanting to have all its eggs in one basket, the company is also working on another project, ‘Novel Anti-Inflammatory Polysaccharides’, to develop a new anti-inflammatory drug.
As a drug discoverer, profits have so far eluded Verona, chaired by Professor Clive Page and steered by chief executive officer Dr Clive Walker. The company lost £1.3m last year, but, after raising £2.3m at 4p, ended 2008 with £2.5m cash.
Shares in Verona, floated four years ago at 2p, reached 6.25p in 2007 before crumbling to 2.13p by last August. Tipped by Growth Company Investor at 4.12p, they have since rallied 40% to 6.62p, and could make further progress if clinical developments go well.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £14.25m
PE Forecast: n/a
Share price: 6.62p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
The Capital Pub Company 31/08/2010
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.
Sectors
